KBI Biopharma vs Lonza: CDMO Comparison
Side-by-side comparison of KBI Biopharma and Lonza on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Lonza holds 3 active EMA GMP certificates; KBI Biopharma does not appear in EudraGMDP.
- Lonza has stronger MHRA / UK coverage (5 compliant certificates vs 1).
On a 13-modality CDMO landscape, both KBI Biopharma and Lonza qualify as AAV manufacturers; KBI Biopharma carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both KBI Biopharma and Lonza qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: KBI Biopharma vs Lonza
Which has the stronger FDA inspection record, KBI Biopharma or Lonza?
Both KBI Biopharma and Lonza maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. KBI Biopharma has 1 FDA inspection on record; Lonza has 2.
How do KBI Biopharma and Lonza compare on European GMP coverage?
KBI Biopharma holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Lonza holds 3 active EMA GMP certificates and 5 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — KBI Biopharma or Lonza?
KBI Biopharma is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Lonza is matched to 1. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for AAV manufacturing — KBI Biopharma or Lonza?
Both KBI Biopharma and Lonza are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
KBI Biopharma carries a Signal Score of 84/100 and Lonza carries 78/100 — a small lead for KBI Biopharma. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →